Summary by Moomoo AI
Raju Prasad, the Chief Financial Officer of CRISPR Therapeutics AG (CRSP), completed a sale of 3,524 shares of common stock on March 15, 2024. The transaction was executed at a price of $72.69 per share, resulting in a total market value of $256,159.56. This sale followed an acquisition of 10,000 shares on March 14, 2024, through the exercise of derivative securities. After these transactions, Prasad's direct holdings in the company amount to 6,476 shares of common stock.